Atopic Dermatitis

A dermatology expert discusses how numerical rating scale (NRS) is used in atopic dermatitis (AD) clinical trials.

A dermatology expert discusses how the standard of care EASI scores have been improving with newer atopic dermatitis (AD) therapies.

Christopher G. Bunick, MD, PhD, provides an overview of clinical trial outcomes in atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

In this interview, Hebert discussed recent positive topline results from the ADORING 1 trial on tapinarof cream for atopic dermatitis patients aged 2 years and older.

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.

Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.